KR20020015310A - 신체적인 성적반응을 변화시키는 방법 - Google Patents

신체적인 성적반응을 변화시키는 방법 Download PDF

Info

Publication number: KR20020015310A
Authority: KR; South Korea
Prior art keywords: pentoramine; supply; feeding; amount supplied; vagina
Prior art date: 1999-04-06
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Withdrawn

Application number

KR1020017012674A

Other languages

English (en)

Korean (ko)

Inventor

포돌스키조셉에스

Original Assignee

로버트 엘. 로브

조나겐, 아이엔씨.

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1999-04-06

Filing date

2000-04-06

Publication date

2002-02-27

2000-04-06 Application filed by 로버트 엘. 로브, 조나겐, 아이엔씨. filed Critical 로버트 엘. 로브

2002-02-27 Publication of KR20020015310A publication Critical patent/KR20020015310A/ko

Status Withdrawn legal-status Critical Current

Links

238000000034 method Methods 0.000 title claims abstract description 153
230000036332 sexual response Effects 0.000 title claims abstract description 56
241000282414 Homo sapiens Species 0.000 title claims description 8
229940124549 vasodilator Drugs 0.000 claims abstract description 75
239000003071 vasodilator agent Substances 0.000 claims abstract description 75
210000001215 vagina Anatomy 0.000 claims abstract description 35
210000004877 mucosa Anatomy 0.000 claims abstract description 29
AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 claims description 51
239000003814 drug Substances 0.000 claims description 42
229940079593 drug Drugs 0.000 claims description 36
XQYZDYMELSJDRZ-UHFFFAOYSA-N papaverine Chemical compound C1=C(OC)C(OC)=CC=C1CC1=NC=CC2=CC(OC)=C(OC)C=C12 XQYZDYMELSJDRZ-UHFFFAOYSA-N 0.000 claims description 23
230000017531 blood circulation Effects 0.000 claims description 22
239000000829 suppository Substances 0.000 claims description 17
239000006071 cream Substances 0.000 claims description 15
VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 claims description 14
210000004392 genitalia Anatomy 0.000 claims description 14
229960001789 papaverine Drugs 0.000 claims description 12
229930008281 A03AD01 - Papaverine Natural products 0.000 claims description 11
QZVCTJOXCFMACW-UHFFFAOYSA-N Phenoxybenzamine Chemical compound C=1C=CC=CC=1CN(CCCl)C(C)COC1=CC=CC=C1 QZVCTJOXCFMACW-UHFFFAOYSA-N 0.000 claims description 8
229960003418 phenoxybenzamine Drugs 0.000 claims description 8
SGTNSNPWRIOYBX-UHFFFAOYSA-N 2-(3,4-dimethoxyphenyl)-5-{[2-(3,4-dimethoxyphenyl)ethyl](methyl)amino}-2-(propan-2-yl)pentanenitrile Chemical compound C1=C(OC)C(OC)=CC=C1CCN(C)CCCC(C#N)(C(C)C)C1=CC=C(OC)C(OC)=C1 SGTNSNPWRIOYBX-UHFFFAOYSA-N 0.000 claims description 7
BCGWQEUPMDMJNV-UHFFFAOYSA-N imipramine Chemical compound C1CC2=CC=CC=C2N(CCCN(C)C)C2=CC=CC=C21 BCGWQEUPMDMJNV-UHFFFAOYSA-N 0.000 claims description 7
229960004801 imipramine Drugs 0.000 claims description 7
229960001722 verapamil Drugs 0.000 claims description 7
SNIOPGDIGTZGOP-UHFFFAOYSA-N Nitroglycerin Chemical compound [O-][N+](=O)OCC(O[N+]([O-])=O)CO[N+]([O-])=O SNIOPGDIGTZGOP-UHFFFAOYSA-N 0.000 claims description 6
239000000006 Nitroglycerin Substances 0.000 claims description 6
VRYMTAVOXVTQEF-UHFFFAOYSA-N acetic acid [4-[2-(dimethylamino)ethoxy]-2-methyl-5-propan-2-ylphenyl] ester Chemical compound CC(C)C1=CC(OC(C)=O)=C(C)C=C1OCCN(C)C VRYMTAVOXVTQEF-UHFFFAOYSA-N 0.000 claims description 6
229960003711 glyceryl trinitrate Drugs 0.000 claims description 6
229960003509 moxisylyte Drugs 0.000 claims description 6
229960002312 tolazoline Drugs 0.000 claims description 6
JIVZKJJQOZQXQB-UHFFFAOYSA-N tolazoline Chemical compound C=1C=CC=CC=1CC1=NCCN1 JIVZKJJQOZQXQB-UHFFFAOYSA-N 0.000 claims description 6
MVQVNTPHUGQQHK-UHFFFAOYSA-N 3-pyridinemethanol Chemical compound OCC1=CC=CN=C1 MVQVNTPHUGQQHK-UHFFFAOYSA-N 0.000 claims description 4
229960004046 apomorphine Drugs 0.000 claims description 4
VMWNQDUVQKEIOC-CYBMUJFWSA-N apomorphine Chemical compound C([C@H]1N(C)CC2)C3=CC=C(O)C(O)=C3C3=C1C2=CC=C3 VMWNQDUVQKEIOC-CYBMUJFWSA-N 0.000 claims description 4
229960004738 nicotinyl alcohol Drugs 0.000 claims description 4
241000282412 Homo Species 0.000 claims description 2
238000004519 manufacturing process Methods 0.000 claims description 2
230000037361 pathway Effects 0.000 abstract description 8
201000001881 impotence Diseases 0.000 description 53
208000010228 Erectile Dysfunction Diseases 0.000 description 50
210000001367 artery Anatomy 0.000 description 22
210000003899 penis Anatomy 0.000 description 21
230000001568 sexual effect Effects 0.000 description 21
230000001856 erectile effect Effects 0.000 description 20
230000004044 response Effects 0.000 description 20
210000003491 skin Anatomy 0.000 description 20
230000000694 effects Effects 0.000 description 17
239000003826 tablet Substances 0.000 description 17
238000003780 insertion Methods 0.000 description 14
230000037431 insertion Effects 0.000 description 14
239000000243 solution Substances 0.000 description 11
PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 9
238000006243 chemical reaction Methods 0.000 description 9
210000003029 clitoris Anatomy 0.000 description 9
230000002792 vascular Effects 0.000 description 9
210000000214 mouth Anatomy 0.000 description 8
210000004400 mucous membrane Anatomy 0.000 description 8
-1 naphthydropuryl Chemical compound 0.000 description 8
229940068196 placebo Drugs 0.000 description 8
239000000902 placebo Substances 0.000 description 8
210000000664 rectum Anatomy 0.000 description 8
230000004087 circulation Effects 0.000 description 7
239000000203 mixture Substances 0.000 description 7
210000001331 nose Anatomy 0.000 description 7
239000006216 vaginal suppository Substances 0.000 description 7
PPWLAQVKIFDULF-UHFFFAOYSA-N 2-phenyl-1h-pyrrolo[2,3-b]pyridine Chemical compound N1C2=NC=CC=C2C=C1C1=CC=CC=C1 PPWLAQVKIFDULF-UHFFFAOYSA-N 0.000 description 6
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 6
239000008280 blood Substances 0.000 description 6
210000004369 blood Anatomy 0.000 description 6
KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 6
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 6
229960003056 phentolamine mesylate Drugs 0.000 description 6
150000003839 salts Chemical class 0.000 description 6
230000024883 vasodilation Effects 0.000 description 6
BLGXFZZNTVWLAY-CCZXDCJGSA-N Yohimbine Natural products C1=CC=C2C(CCN3C[C@@H]4CC[C@@H](O)[C@H]([C@H]4C[C@H]33)C(=O)OC)=C3NC2=C1 BLGXFZZNTVWLAY-CCZXDCJGSA-N 0.000 description 5
239000002160 alpha blocker Substances 0.000 description 5
150000001412 amines Chemical class 0.000 description 5
BLGXFZZNTVWLAY-UHFFFAOYSA-N beta-Yohimbin Natural products C1=CC=C2C(CCN3CC4CCC(O)C(C4CC33)C(=O)OC)=C3NC2=C1 BLGXFZZNTVWLAY-UHFFFAOYSA-N 0.000 description 5
230000008602 contraction Effects 0.000 description 5
210000005226 corpus cavernosum Anatomy 0.000 description 5
229960001999 phentolamine Drugs 0.000 description 5
MRBDMNSDAVCSSF-UHFFFAOYSA-N phentolamine Chemical compound C1=CC(C)=CC=C1N(C=1C=C(O)C=CC=1)CC1=NCCN1 MRBDMNSDAVCSSF-UHFFFAOYSA-N 0.000 description 5
230000004936 stimulating effect Effects 0.000 description 5
230000002889 sympathetic effect Effects 0.000 description 5
238000012360 testing method Methods 0.000 description 5
239000002550 vasoactive agent Substances 0.000 description 5
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 5
229960000317 yohimbine Drugs 0.000 description 5
BLGXFZZNTVWLAY-SCYLSFHTSA-N yohimbine Chemical compound C1=CC=C2C(CCN3C[C@@H]4CC[C@H](O)[C@@H]([C@H]4C[C@H]33)C(=O)OC)=C3NC2=C1 BLGXFZZNTVWLAY-SCYLSFHTSA-N 0.000 description 5
AADVZSXPNRLYLV-UHFFFAOYSA-N yohimbine carboxylic acid Natural products C1=CC=C2C(CCN3CC4CCC(C(C4CC33)C(O)=O)O)=C3NC2=C1 AADVZSXPNRLYLV-UHFFFAOYSA-N 0.000 description 5
PVNIIMVLHYAWGP-UHFFFAOYSA-N Niacin Chemical compound OC(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-N 0.000 description 4
230000008321 arterial blood flow Effects 0.000 description 4
RYYVLZVUVIJVGH-UHFFFAOYSA-N caffeine Chemical compound CN1C(=O)N(C)C(=O)C2=C1N=CN2C RYYVLZVUVIJVGH-UHFFFAOYSA-N 0.000 description 4
230000001364 causal effect Effects 0.000 description 4
208000035475 disorder Diseases 0.000 description 4
230000009986 erectile function Effects 0.000 description 4
239000012458 free base Substances 0.000 description 4
235000011187 glycerol Nutrition 0.000 description 4
210000003090 iliac artery Anatomy 0.000 description 4
230000006872 improvement Effects 0.000 description 4
230000001965 increasing effect Effects 0.000 description 4
210000002850 nasal mucosa Anatomy 0.000 description 4
229940082615 organic nitrates used in cardiac disease Drugs 0.000 description 4
230000000638 stimulation Effects 0.000 description 4
210000002435 tendon Anatomy 0.000 description 4
230000032258 transport Effects 0.000 description 4
230000006492 vascular dysfunction Effects 0.000 description 4
QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 3
108010010803 Gelatin Proteins 0.000 description 3
241001313288 Labia Species 0.000 description 3
GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 3
OFOBLEOULBTSOW-UHFFFAOYSA-N Malonic acid Chemical compound OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 3
OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
240000002853 Nelumbo nucifera Species 0.000 description 3
235000006508 Nelumbo nucifera Nutrition 0.000 description 3
206010028980 Neoplasm Diseases 0.000 description 3
MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 3
229920002367 Polyisobutene Polymers 0.000 description 3
HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
239000000150 Sympathomimetic Substances 0.000 description 3
206010054880 Vascular insufficiency Diseases 0.000 description 3
230000002159 abnormal effect Effects 0.000 description 3
239000002253 acid Substances 0.000 description 3
230000009471 action Effects 0.000 description 3
239000000853 adhesive Substances 0.000 description 3
230000001070 adhesive effect Effects 0.000 description 3
150000001875 compounds Chemical class 0.000 description 3
230000002124 endocrine Effects 0.000 description 3
239000000499 gel Substances 0.000 description 3
239000008273 gelatin Substances 0.000 description 3
229920000159 gelatin Polymers 0.000 description 3
235000019322 gelatine Nutrition 0.000 description 3
235000011852 gelatine desserts Nutrition 0.000 description 3
230000003993 interaction Effects 0.000 description 3
239000008101 lactose Substances 0.000 description 3
239000010410 layer Substances 0.000 description 3
235000011475 lollipops Nutrition 0.000 description 3
HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 3
210000004379 membrane Anatomy 0.000 description 3
239000012528 membrane Substances 0.000 description 3
239000007922 nasal spray Substances 0.000 description 3
239000002674 ointment Substances 0.000 description 3
208000023577 vascular insufficiency disease Diseases 0.000 description 3
210000005166 vasculature Anatomy 0.000 description 3
230000002883 vasorelaxation effect Effects 0.000 description 3
QHZLMUACJMDIAE-UHFFFAOYSA-N 1-monopalmitoylglycerol Chemical compound CCCCCCCCCCCCCCCC(=O)OCC(O)CO QHZLMUACJMDIAE-UHFFFAOYSA-N 0.000 description 2
QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 2
CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 2
RPTUSVTUFVMDQK-UHFFFAOYSA-N Hidralazin Chemical compound C1=CC=C2C(NN)=NN=CC2=C1 RPTUSVTUFVMDQK-UHFFFAOYSA-N 0.000 description 2
LPHGQDQBBGAPDZ-UHFFFAOYSA-N Isocaffeine Natural products CN1C(=O)N(C)C(=O)C2=C1N(C)C=N2 LPHGQDQBBGAPDZ-UHFFFAOYSA-N 0.000 description 2
241000750002 Nestor Species 0.000 description 2
NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 2
UIIMBOGNXHQVGW-DEQYMQKBSA-M Sodium bicarbonate-14C Chemical compound [Na+].O[14C]([O-])=O UIIMBOGNXHQVGW-DEQYMQKBSA-M 0.000 description 2
QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
206010047141 Vasodilatation Diseases 0.000 description 2
206010052428 Wound Diseases 0.000 description 2
208000027418 Wounds and injury Diseases 0.000 description 2
238000010521 absorption reaction Methods 0.000 description 2
239000000674 adrenergic antagonist Substances 0.000 description 2
HSNWZBCBUUSSQD-UHFFFAOYSA-N amyl nitrate Chemical compound CCCCCO[N+]([O-])=O HSNWZBCBUUSSQD-UHFFFAOYSA-N 0.000 description 2
210000003403 autonomic nervous system Anatomy 0.000 description 2
210000004204 blood vessel Anatomy 0.000 description 2
229960001948 caffeine Drugs 0.000 description 2
VJEONQKOZGKCAK-UHFFFAOYSA-N caffeine Natural products CN1C(=O)N(C)C(=O)C2=C1C=CN2C VJEONQKOZGKCAK-UHFFFAOYSA-N 0.000 description 2
230000008859 change Effects 0.000 description 2
238000007796 conventional method Methods 0.000 description 2
239000013078 crystal Substances 0.000 description 2
206010012601 diabetes mellitus Diseases 0.000 description 2
201000010099 disease Diseases 0.000 description 2
238000002474 experimental method Methods 0.000 description 2
239000012530 fluid Substances 0.000 description 2
210000003953 foreskin Anatomy 0.000 description 2
238000004108 freeze drying Methods 0.000 description 2
XZZXIYZZBJDEEP-UHFFFAOYSA-N imipramine hydrochloride Chemical compound [Cl-].C1CC2=CC=CC=C2N(CCC[NH+](C)C)C2=CC=CC=C21 XZZXIYZZBJDEEP-UHFFFAOYSA-N 0.000 description 2
230000001771 impaired effect Effects 0.000 description 2
230000001939 inductive effect Effects 0.000 description 2
238000002347 injection Methods 0.000 description 2
239000007924 injection Substances 0.000 description 2
208000014674 injury Diseases 0.000 description 2
150000002632 lipids Chemical class 0.000 description 2
210000004185 liver Anatomy 0.000 description 2
235000010355 mannitol Nutrition 0.000 description 2
238000005259 measurement Methods 0.000 description 2
LXCFILQKKLGQFO-UHFFFAOYSA-N methylparaben Chemical compound COC(=O)C1=CC=C(O)C=C1 LXCFILQKKLGQFO-UHFFFAOYSA-N 0.000 description 2
239000002480 mineral oil Substances 0.000 description 2
235000010446 mineral oil Nutrition 0.000 description 2
210000002200 mouth mucosa Anatomy 0.000 description 2
229940097496 nasal spray Drugs 0.000 description 2
229960003512 nicotinic acid Drugs 0.000 description 2
235000001968 nicotinic acid Nutrition 0.000 description 2
239000011664 nicotinic acid Substances 0.000 description 2
230000000149 penetrating effect Effects 0.000 description 2
229920000728 polyester Polymers 0.000 description 2
BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 2
238000002360 preparation method Methods 0.000 description 2
230000008569 process Effects 0.000 description 2
GMVPRGQOIOIIMI-DWKJAMRDSA-N prostaglandin E1 Chemical compound CCCCC[C@H](O)\C=C\[C@H]1[C@H](O)CC(=O)[C@@H]1CCCCCCC(O)=O GMVPRGQOIOIIMI-DWKJAMRDSA-N 0.000 description 2
YGSDEFSMJLZEOE-UHFFFAOYSA-N salicylic acid Chemical compound OC(=O)C1=CC=CC=C1O YGSDEFSMJLZEOE-UHFFFAOYSA-N 0.000 description 2
210000002460 smooth muscle Anatomy 0.000 description 2
230000000392 somatic effect Effects 0.000 description 2
230000002269 spontaneous effect Effects 0.000 description 2
210000002784 stomach Anatomy 0.000 description 2
239000007929 subcutaneous injection Substances 0.000 description 2
238000010254 subcutaneous injection Methods 0.000 description 2
230000009885 systemic effect Effects 0.000 description 2
238000002560 therapeutic procedure Methods 0.000 description 2
238000001931 thermography Methods 0.000 description 2
230000000699 topical effect Effects 0.000 description 2
230000008733 trauma Effects 0.000 description 2
238000002604 ultrasonography Methods 0.000 description 2
230000002485 urinary effect Effects 0.000 description 2
239000000029 vaginal gel Substances 0.000 description 2
229940120293 vaginal suppository Drugs 0.000 description 2
230000004218 vascular function Effects 0.000 description 2
LBLYYCQCTBFVLH-UHFFFAOYSA-N 2-Methylbenzenesulfonic acid Chemical compound CC1=CC=CC=C1S(O)(=O)=O LBLYYCQCTBFVLH-UHFFFAOYSA-N 0.000 description 1
NKQVYJRZBVRXRU-UHFFFAOYSA-N 2-methyl-2-(methylamino)propanenitrile Chemical compound CNC(C)(C)C#N NKQVYJRZBVRXRU-UHFFFAOYSA-N 0.000 description 1
BPQZYOJIXDMZSX-UHFFFAOYSA-N 4-[(3-carboxy-2-hydroxynaphthalen-1-yl)methyl]-3-hydroxynaphthalene-2-carboxylic acid;3-(5,6-dihydrobenzo[b][1]benzazepin-11-yl)-n,n-dimethylpropan-1-amine Chemical compound C1CC2=CC=CC=C2N(CCCN(C)C)C2=CC=CC=C21.C1CC2=CC=CC=C2N(CCCN(C)C)C2=CC=CC=C21.C1=CC=C2C(CC=3C4=CC=CC=C4C=C(C=3O)C(=O)O)=C(O)C(C(O)=O)=CC2=C1 BPQZYOJIXDMZSX-UHFFFAOYSA-N 0.000 description 1
BMUKKTUHUDJSNZ-UHFFFAOYSA-N 4-[1-hydroxy-2-(1-phenoxypropan-2-ylamino)propyl]phenol Chemical compound C=1C=C(O)C=CC=1C(O)C(C)NC(C)COC1=CC=CC=C1 BMUKKTUHUDJSNZ-UHFFFAOYSA-N 0.000 description 1
PTGXAUBQBSGPKF-UHFFFAOYSA-N 4-[1-hydroxy-2-(4-phenylbutan-2-ylamino)propyl]phenol Chemical compound C=1C=C(O)C=CC=1C(O)C(C)NC(C)CCC1=CC=CC=C1 PTGXAUBQBSGPKF-UHFFFAOYSA-N 0.000 description 1
QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
241000416162 Astragalus gummifer Species 0.000 description 1
206010061666 Autonomic neuropathy Diseases 0.000 description 1
LSNNMFCWUKXFEE-UHFFFAOYSA-M Bisulfite Chemical compound OS([O-])=O LSNNMFCWUKXFEE-UHFFFAOYSA-M 0.000 description 1
208000031872 Body Remains Diseases 0.000 description 1
229940127291 Calcium channel antagonist Drugs 0.000 description 1
208000024172 Cardiovascular disease Diseases 0.000 description 1
108010078791 Carrier Proteins Proteins 0.000 description 1
206010010904 Convulsion Diseases 0.000 description 1
229920002261 Corn starch Polymers 0.000 description 1
PHOQVHQSTUBQQK-SQOUGZDYSA-N D-glucono-1,5-lactone Chemical compound OC[C@H]1OC(=O)[C@H](O)[C@@H](O)[C@@H]1O PHOQVHQSTUBQQK-SQOUGZDYSA-N 0.000 description 1
208000016192 Demyelinating disease Diseases 0.000 description 1
206010016654 Fibrosis Diseases 0.000 description 1
108700012941 GNRH1 Proteins 0.000 description 1
239000000579 Gonadotropin-Releasing Hormone Substances 0.000 description 1
206010018691 Granuloma Diseases 0.000 description 1
239000004354 Hydroxyethyl cellulose Substances 0.000 description 1
229920000663 Hydroxyethyl cellulose Polymers 0.000 description 1
206010020565 Hyperaemia Diseases 0.000 description 1
DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
QAQJMLQRFWZOBN-LAUBAEHRSA-N L-ascorbyl-6-palmitate Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](O)[C@H]1OC(=O)C(O)=C1O QAQJMLQRFWZOBN-LAUBAEHRSA-N 0.000 description 1
239000011786 L-ascorbyl-6-palmitate Substances 0.000 description 1
239000004166 Lanolin Substances 0.000 description 1
241000124008 Mammalia Species 0.000 description 1
229930195725 Mannitol Natural products 0.000 description 1
241000699670 Mus sp. Species 0.000 description 1
KBAFPSLPKGSANY-UHFFFAOYSA-N Naftidrofuryl Chemical compound C=1C=CC2=CC=CC=C2C=1CC(C(=O)OCCN(CC)CC)CC1CCCO1 KBAFPSLPKGSANY-UHFFFAOYSA-N 0.000 description 1
206010028735 Nasal congestion Diseases 0.000 description 1
101800000989 Oxytocin Proteins 0.000 description 1
XNOPRXBHLZRZKH-UHFFFAOYSA-N Oxytocin Natural products N1C(=O)C(N)CSSCC(C(=O)N2C(CCC2)C(=O)NC(CC(C)C)C(=O)NCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(CCC(N)=O)NC(=O)C(C(C)CC)NC(=O)C1CC1=CC=C(O)C=C1 XNOPRXBHLZRZKH-UHFFFAOYSA-N 0.000 description 1
102100031951 Oxytocin-neurophysin 1 Human genes 0.000 description 1
206010056303 Painful erection Diseases 0.000 description 1
206010033892 Paraplegia Diseases 0.000 description 1
206010061336 Pelvic neoplasm Diseases 0.000 description 1
208000004362 Penile Induration Diseases 0.000 description 1
208000020758 Peyronie disease Diseases 0.000 description 1
208000007913 Pituitary Neoplasms Diseases 0.000 description 1
201000005746 Pituitary adenoma Diseases 0.000 description 1
206010061538 Pituitary tumour benign Diseases 0.000 description 1
239000002202 Polyethylene glycol Substances 0.000 description 1
239000004743 Polypropylene Substances 0.000 description 1
FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
206010041349 Somnolence Diseases 0.000 description 1
229920001615 Tragacanth Polymers 0.000 description 1
DOQPXTMNIUCOSY-UHFFFAOYSA-N [4-cyano-4-(3,4-dimethoxyphenyl)-5-methylhexyl]-[2-(3,4-dimethoxyphenyl)ethyl]-methylazanium;chloride Chemical compound [H+].[Cl-].C1=C(OC)C(OC)=CC=C1CCN(C)CCCC(C#N)(C(C)C)C1=CC=C(OC)C(OC)=C1 DOQPXTMNIUCOSY-UHFFFAOYSA-N 0.000 description 1
210000001015 abdomen Anatomy 0.000 description 1
150000007513 acids Chemical class 0.000 description 1
NIXOWILDQLNWCW-UHFFFAOYSA-N acrylic acid group Chemical group C(C=C)(=O)O NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 description 1
239000012790 adhesive layer Substances 0.000 description 1
XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 1
229910052782 aluminium Inorganic materials 0.000 description 1
229910000147 aluminium phosphate Inorganic materials 0.000 description 1
229910021529 ammonia Inorganic materials 0.000 description 1
210000003484 anatomy Anatomy 0.000 description 1
239000003420 antiserotonin agent Substances 0.000 description 1
239000002249 anxiolytic agent Substances 0.000 description 1
210000000702 aorta abdominal Anatomy 0.000 description 1
239000007864 aqueous solution Substances 0.000 description 1
230000037007 arousal Effects 0.000 description 1
230000006497 arterial abnormality Effects 0.000 description 1
235000010323 ascorbic acid Nutrition 0.000 description 1
229960005070 ascorbic acid Drugs 0.000 description 1
239000011668 ascorbic acid Substances 0.000 description 1
235000010385 ascorbyl palmitate Nutrition 0.000 description 1
210000001142 back Anatomy 0.000 description 1
230000004888 barrier function Effects 0.000 description 1
239000002585 base Substances 0.000 description 1
230000009286 beneficial effect Effects 0.000 description 1
230000008901 benefit Effects 0.000 description 1
239000002876 beta blocker Substances 0.000 description 1
229940030611 beta-adrenergic blocking agent Drugs 0.000 description 1
239000011230 binding agent Substances 0.000 description 1
230000015572 biosynthetic process Effects 0.000 description 1
239000002981 blocking agent Substances 0.000 description 1
230000036772 blood pressure Effects 0.000 description 1
210000000988 bone and bone Anatomy 0.000 description 1
229960003455 buphenine Drugs 0.000 description 1
239000000480 calcium channel blocker Substances 0.000 description 1
201000011510 cancer Diseases 0.000 description 1
150000001735 carboxylic acids Chemical class 0.000 description 1
229940124461 cardiostimulant Drugs 0.000 description 1
230000009084 cardiovascular function Effects 0.000 description 1
239000000969 carrier Substances 0.000 description 1
150000003943 catecholamines Chemical class 0.000 description 1
210000003169 central nervous system Anatomy 0.000 description 1
230000002490 cerebral effect Effects 0.000 description 1
210000003679 cervix uteri Anatomy 0.000 description 1
239000003795 chemical substances by application Substances 0.000 description 1
229940112822 chewing gum Drugs 0.000 description 1
235000015218 chewing gum Nutrition 0.000 description 1
230000001684 chronic effect Effects 0.000 description 1
208000020832 chronic kidney disease Diseases 0.000 description 1
208000022831 chronic renal failure syndrome Diseases 0.000 description 1
230000007882 cirrhosis Effects 0.000 description 1
208000019425 cirrhosis of liver Diseases 0.000 description 1
235000015165 citric acid Nutrition 0.000 description 1
229940110456 cocoa butter Drugs 0.000 description 1
235000019868 cocoa butter Nutrition 0.000 description 1
229940075614 colloidal silicon dioxide Drugs 0.000 description 1
230000006835 compression Effects 0.000 description 1
238000007906 compression Methods 0.000 description 1
235000009508 confectionery Nutrition 0.000 description 1
208000027744 congestion Diseases 0.000 description 1
239000008120 corn starch Substances 0.000 description 1
239000003431 cross linking reagent Substances 0.000 description 1
238000002425 crystallisation Methods 0.000 description 1
230000008025 crystallization Effects 0.000 description 1
108700027018 deaminooxytocin Proteins 0.000 description 1
230000007423 decrease Effects 0.000 description 1
230000007812 deficiency Effects 0.000 description 1
229940124447 delivery agent Drugs 0.000 description 1
GTYWGUNQAMYZPF-QPLNMOKZSA-N demoxytocin Chemical compound C([C@H]1C(=O)N[C@H](C(N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CSSCCC(=O)N1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC(C)C)C(=O)NCC(N)=O)=O)[C@@H](C)CC)C1=CC=C(O)C=C1 GTYWGUNQAMYZPF-QPLNMOKZSA-N 0.000 description 1
229960000477 demoxytocin Drugs 0.000 description 1
238000003745 diagnosis Methods 0.000 description 1
235000014113 dietary fatty acids Nutrition 0.000 description 1
XEYBHCRIKKKOSS-UHFFFAOYSA-N disodium;azanylidyneoxidanium;iron(2+);pentacyanide Chemical compound [Na+].[Na+].[Fe+2].N#[C-].N#[C-].N#[C-].N#[C-].N#[C-].[O+]#N XEYBHCRIKKKOSS-UHFFFAOYSA-N 0.000 description 1
208000002173 dizziness Diseases 0.000 description 1
238000001647 drug administration Methods 0.000 description 1
230000000857 drug effect Effects 0.000 description 1
230000004064 dysfunction Effects 0.000 description 1
230000002526 effect on cardiovascular system Effects 0.000 description 1
229920001971 elastomer Polymers 0.000 description 1
230000008451 emotion Effects 0.000 description 1
210000003372 endocrine gland Anatomy 0.000 description 1
210000000750 endocrine system Anatomy 0.000 description 1
206010015037 epilepsy Diseases 0.000 description 1
210000005225 erectile tissue Anatomy 0.000 description 1
210000003238 esophagus Anatomy 0.000 description 1
229940011871 estrogen Drugs 0.000 description 1
239000000262 estrogen Substances 0.000 description 1
238000011156 evaluation Methods 0.000 description 1
230000005284 excitation Effects 0.000 description 1
239000000194 fatty acid Substances 0.000 description 1
229930195729 fatty acid Natural products 0.000 description 1
150000004665 fatty acids Chemical class 0.000 description 1
239000000796 flavoring agent Substances 0.000 description 1
238000007647 flexography Methods 0.000 description 1
235000013355 food flavoring agent Nutrition 0.000 description 1
230000006870 function Effects 0.000 description 1
235000012209 glucono delta-lactone Nutrition 0.000 description 1
229960003681 gluconolactone Drugs 0.000 description 1
210000002149 gonad Anatomy 0.000 description 1
230000002710 gonadal effect Effects 0.000 description 1
230000003054 hormonal effect Effects 0.000 description 1
229960002474 hydralazine Drugs 0.000 description 1
239000001257 hydrogen Substances 0.000 description 1
229910052739 hydrogen Inorganic materials 0.000 description 1
125000004435 hydrogen atom Chemical class [H]* 0.000 description 1
235000019866 hydrogenated palm kernel oil Nutrition 0.000 description 1
239000008172 hydrogenated vegetable oil Substances 0.000 description 1
230000007062 hydrolysis Effects 0.000 description 1
238000006460 hydrolysis reaction Methods 0.000 description 1
PIPZGJSEDRMUAW-VJDCAHTMSA-N hydron;methyl (1s,15r,18s,19r,20s)-18-hydroxy-1,3,11,12,14,15,16,17,18,19,20,21-dodecahydroyohimban-19-carboxylate;chloride Chemical compound Cl.C1=CC=C2C(CCN3C[C@@H]4CC[C@H](O)[C@@H]([C@H]4C[C@H]33)C(=O)OC)=C3NC2=C1 PIPZGJSEDRMUAW-VJDCAHTMSA-N 0.000 description 1
229940071826 hydroxyethyl cellulose Drugs 0.000 description 1
235000019447 hydroxyethyl cellulose Nutrition 0.000 description 1
229940031574 hydroxymethyl cellulose Drugs 0.000 description 1
229920003063 hydroxymethyl cellulose Polymers 0.000 description 1
208000031424 hyperprolactinemia Diseases 0.000 description 1
229960002102 imipramine hydrochloride Drugs 0.000 description 1
229960000375 imipramine pamoate Drugs 0.000 description 1
208000015181 infectious disease Diseases 0.000 description 1
230000036512 infertility Effects 0.000 description 1
208000000509 infertility Diseases 0.000 description 1
231100000535 infertility Toxicity 0.000 description 1
229910052500 inorganic mineral Inorganic materials 0.000 description 1
239000011229 interlayer Substances 0.000 description 1
230000016507 interphase Effects 0.000 description 1
210000000936 intestine Anatomy 0.000 description 1
230000001788 irregular Effects 0.000 description 1
229960004819 isoxsuprine Drugs 0.000 description 1
229960004164 isoxsuprine hydrochloride Drugs 0.000 description 1
235000019388 lanolin Nutrition 0.000 description 1
229940039717 lanolin Drugs 0.000 description 1
230000003902 lesion Effects 0.000 description 1
230000003908 liver function Effects 0.000 description 1
239000007937 lozenge Substances 0.000 description 1
230000001050 lubricating effect Effects 0.000 description 1
235000019359 magnesium stearate Nutrition 0.000 description 1
VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
239000011976 maleic acid Substances 0.000 description 1
230000036210 malignancy Effects 0.000 description 1
239000000594 mannitol Substances 0.000 description 1
230000000873 masking effect Effects 0.000 description 1
235000010270 methyl p-hydroxybenzoate Nutrition 0.000 description 1
239000004292 methyl p-hydroxybenzoate Substances 0.000 description 1
229960002216 methylparaben Drugs 0.000 description 1
125000004170 methylsulfonyl group Chemical group [H]C([H])([H])S(*)(=O)=O 0.000 description 1
235000010755 mineral Nutrition 0.000 description 1
239000011707 mineral Substances 0.000 description 1
150000007522 mineralic acids Chemical class 0.000 description 1
229940035363 muscle relaxants Drugs 0.000 description 1
210000002464 muscle smooth vascular Anatomy 0.000 description 1
239000003158 myorelaxant agent Substances 0.000 description 1
229960001132 naftidrofuryl Drugs 0.000 description 1
210000003928 nasal cavity Anatomy 0.000 description 1
230000000926 neurological effect Effects 0.000 description 1
210000002445 nipple Anatomy 0.000 description 1
239000004745 nonwoven fabric Substances 0.000 description 1
229940126701 oral medication Drugs 0.000 description 1
210000000056 organ Anatomy 0.000 description 1
150000007524 organic acids Chemical class 0.000 description 1
235000006408 oxalic acid Nutrition 0.000 description 1
XNOPRXBHLZRZKH-DSZYJQQASA-N oxytocin Chemical compound C([C@H]1C(=O)N[C@H](C(N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CSSC[C@H](N)C(=O)N1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC(C)C)C(=O)NCC(N)=O)=O)[C@@H](C)CC)C1=CC=C(O)C=C1 XNOPRXBHLZRZKH-DSZYJQQASA-N 0.000 description 1
229960001723 oxytocin Drugs 0.000 description 1
FJKROLUGYXJWQN-UHFFFAOYSA-N papa-hydroxy-benzoic acid Natural products OC(=O)C1=CC=C(O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-N 0.000 description 1
230000037368 penetrate the skin Effects 0.000 description 1
210000000578 peripheral nerve Anatomy 0.000 description 1
210000001428 peripheral nervous system Anatomy 0.000 description 1
210000003800 pharynx Anatomy 0.000 description 1
238000013186 photoplethysmography Methods 0.000 description 1
230000000704 physical effect Effects 0.000 description 1
208000021310 pituitary gland adenoma Diseases 0.000 description 1
239000002798 polar solvent Substances 0.000 description 1
229920001200 poly(ethylene-vinyl acetate) Polymers 0.000 description 1
229920006267 polyester film Polymers 0.000 description 1
229920001223 polyethylene glycol Polymers 0.000 description 1
229940050929 polyethylene glycol 3350 Drugs 0.000 description 1
229920001155 polypropylene Polymers 0.000 description 1
229910000027 potassium carbonate Inorganic materials 0.000 description 1
201000011264 priapism Diseases 0.000 description 1
230000000750 progressive effect Effects 0.000 description 1
238000011471 prostatectomy Methods 0.000 description 1
230000004800 psychological effect Effects 0.000 description 1
210000003689 pubic bone Anatomy 0.000 description 1
230000009257 reactivity Effects 0.000 description 1
239000006215 rectal suppository Substances 0.000 description 1
230000001105 regulatory effect Effects 0.000 description 1
230000033904 relaxation of vascular smooth muscle Effects 0.000 description 1
229920005989 resin Polymers 0.000 description 1
239000011347 resin Substances 0.000 description 1
229960004889 salicylic acid Drugs 0.000 description 1
230000028327 secretion Effects 0.000 description 1
208000012201 sexual and gender identity disease Diseases 0.000 description 1
208000015891 sexual disease Diseases 0.000 description 1
229910052814 silicon oxide Inorganic materials 0.000 description 1
239000000050 smooth muscle relaxant Substances 0.000 description 1
239000011734 sodium Substances 0.000 description 1
229940083542 sodium Drugs 0.000 description 1
229910052708 sodium Inorganic materials 0.000 description 1
239000011780 sodium chloride Substances 0.000 description 1
229940083618 sodium nitroprusside Drugs 0.000 description 1
239000002904 solvent Substances 0.000 description 1
230000006641 stabilisation Effects 0.000 description 1
238000011105 stabilization Methods 0.000 description 1
239000000021 stimulant Substances 0.000 description 1
239000000126 substance Substances 0.000 description 1
239000006228 supernatant Substances 0.000 description 1
230000002459 sustained effect Effects 0.000 description 1
230000009747 swallowing Effects 0.000 description 1
230000006016 thyroid dysfunction Effects 0.000 description 1
229940041597 tofranil Drugs 0.000 description 1
VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 1
230000000472 traumatic effect Effects 0.000 description 1
238000002379 ultrasonic velocimetry Methods 0.000 description 1
210000003708 urethra Anatomy 0.000 description 1
210000004291 uterus Anatomy 0.000 description 1
229940044950 vaginal gel Drugs 0.000 description 1
239000000003 vaginal tablet Substances 0.000 description 1
230000000304 vasodilatating effect Effects 0.000 description 1
230000006499 vasodilator function Effects 0.000 description 1
230000000982 vasogenic effect Effects 0.000 description 1
210000003462 vein Anatomy 0.000 description 1
229960000881 verapamil hydrochloride Drugs 0.000 description 1
229940045860 white wax Drugs 0.000 description 1
229960000949 yohimbine hydrochloride Drugs 0.000 description 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/473—Quinolines; Isoquinolines ortho- or peri-condensed with carbocyclic ring systems, e.g. acridines, phenanthridines
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A61K31/138—Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
- A61K31/222—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin with compounds having aromatic groups, e.g. dipivefrine, ibopamine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
- A61K31/341—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide not condensed with another ring, e.g. ranitidine, furosemide, bufetolol, muscarine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/417—Imidazole-alkylamines, e.g. histamine, phentolamine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4174—Arylalkylimidazoles, e.g. oxymetazolin, naphazoline, miconazole
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/472—Non-condensed isoquinolines, e.g. papaverine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Life Sciences & Earth Sciences (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Epidemiology (AREA)
Emergency Medicine (AREA)
Organic Chemistry (AREA)
Endocrinology (AREA)
Reproductive Health (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Gynecology & Obstetrics (AREA)
Medicinal Preparation (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

KR1020017012674A 1999-04-06 2000-04-06 신체적인 성적반응을 변화시키는 방법 Withdrawn KR20020015310A (ko)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
US12791099P	1999-04-06	1999-04-06
US60/127,910		1999-04-06
PCT/US2000/009112 WO2000059491A2 (fr)	1999-04-06	2000-04-06	Methodes permettant de moduler la reponse sexuelle chez les humains

Publications (1)

Publication Number	Publication Date
KR20020015310A true KR20020015310A (ko)	2002-02-27

Family

ID=22432589

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
KR1020017012674A Withdrawn KR20020015310A (ko)	1999-04-06	2000-04-06	신체적인 성적반응을 변화시키는 방법

Country Status (10)

Country	Link
EP (1)	EP1220666A2 (fr)
JP (1)	JP2002541100A (fr)
KR (1)	KR20020015310A (fr)
CN (1)	CN1374861A (fr)
AU (1)	AU4203600A (fr)
BR (1)	BR0009583A (fr)
CA (1)	CA2366903A1 (fr)
MX (1)	MXPA01010021A (fr)
NO (1)	NO20014827L (fr)
WO (1)	WO2000059491A2 (fr)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
GB0130704D0 (en) *	2001-12-21	2002-02-06	Glaxo Group Ltd	New use
US8939889B1 (en)	2013-08-22	2015-01-27	Coloplast A/S	Pump bulb for an implantable penile prosthetic

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
IT1221826B (it) *	1988-06-08	1990-07-12	Medico Harvey Srl Centro	Preparato per uso topico per il trattamento terapeutico dell impotentia coeundi
US5565466A (en) *	1993-08-13	1996-10-15	Zonagen, Inc.	Methods for modulating the human sexual response
US5731339A (en) *	1995-04-28	1998-03-24	Zonagen, Inc.	Methods and formulations for modulating the human sexual response
US6251436B1 (en) *	1995-09-29	2001-06-26	L.A.M. Pharmaceutical Corporation	Drug preparations for treating sexual dysfunction
US5952006A (en) *	1995-09-29	1999-09-14	L.A.M. Pharmaceuticals, Llc	Drug preparations for treating impotency
KR20010012721A (ko) *	1997-05-19	2001-02-26	조나젠 인코포레이티드	인간의 성적 반응을 조정하기 위한 복합 요법
AU751182B2 (en) *	1997-12-02	2002-08-08	Archimedes Development Limited	Compositions for nasal administration
US6011043A (en) *	1998-06-19	2000-01-04	Schering Corporation	Combination of phentolamine and apomorphine for the treatment of human sexual function and dysfunction
US6486207B2 (en) *	1998-12-10	2002-11-26	Nexmed (Holdings), Inc.	Compositions and methods for amelioration of human female sexual dysfunction

2000
- 2000-04-06 CN CN00807879A patent/CN1374861A/zh active Pending
- 2000-04-06 EP EP00921760A patent/EP1220666A2/fr not_active Withdrawn
- 2000-04-06 MX MXPA01010021A patent/MXPA01010021A/es unknown
- 2000-04-06 AU AU42036/00A patent/AU4203600A/en not_active Abandoned
- 2000-04-06 BR BR0009583-4A patent/BR0009583A/pt not_active Application Discontinuation
- 2000-04-06 JP JP2000609055A patent/JP2002541100A/ja not_active Withdrawn
- 2000-04-06 WO PCT/US2000/009112 patent/WO2000059491A2/fr not_active Ceased
- 2000-04-06 KR KR1020017012674A patent/KR20020015310A/ko not_active Withdrawn
- 2000-04-06 CA CA002366903A patent/CA2366903A1/fr not_active Abandoned
2001
- 2001-10-04 NO NO20014827A patent/NO20014827L/no not_active Application Discontinuation

Also Published As

Publication number	Publication date
NO20014827D0 (no)	2001-10-04
AU4203600A (en)	2000-10-23
CA2366903A1 (fr)	2000-10-12
BR0009583A (pt)	2002-06-11
NO20014827L (no)	2001-12-04
JP2002541100A (ja)	2002-12-03
WO2000059491A2 (fr)	2000-10-12
MXPA01010021A (es)	2002-07-30
CN1374861A (zh)	2002-10-16
WO2000059491A3 (fr)	2002-05-02
EP1220666A2 (fr)	2002-07-10

Publication	Publication Date	Title
US5565466A (en)	1996-10-15	Methods for modulating the human sexual response
RU2177786C2 (ru)	2002-01-10	Составы для модулирования сексуальной реакции человека
JP2009280621A (ja)	2009-12-03	ヒトの性応答を調節するための組み合わせ治療
JP2002518435A (ja)	2002-06-25	女性の性機能不全の治療または改善のための方法および組成物
KR20020015310A (ko)	2002-02-27	신체적인 성적반응을 변화시키는 방법
AU696815C (en)	1999-06-24	Methods for modulating the human sexual response
AU723242B2 (en)	2000-08-24	Methods for modulating the human sexual response
US20030207891A1 (en)	2003-11-06	Combination therapy for modulating the human sexual response

Legal Events

Date	Code	Title	Description
2001-10-04	PA0105	International application	Patent event date: 20011004 Patent event code: PA01051R01D Comment text: International Patent Application
2002-02-27	PG1501	Laying open of application
2005-04-07	PC1203	Withdrawal of no request for examination
2005-04-07	WITN	Application deemed withdrawn, e.g. because no request for examination was filed or no examination fee was paid